Search ARM

2018 Annual Report - Europe


This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

European Sector Landscape

241+

Regenerative Medicine / Advanced Therapies
Companies based in Europe/Israel

Total 2018 European/Israeli Financings

Total
Global Financing

$2.2 Billion
Approximately €1.9 Billion

 40%

Increase from 2017

Gene & Gene-modified
Cell Therapy

$1.9 Billion
Approximately €1.7 Billion

 117%

Increase from 2017

Cell
Therapy

$884.7 Million
Approximately €885 Million

 2%

Decrease from 2017

Tissue
Engineering

$73.3 Million
Approximately €64 Million

 41%

Decrease from 2017

216

Clinical Trials
Sponsored by a European or Israeli
developer as of EOY 2018

Clinical Trial by Technology Type

Clinical Trials by Phase

Gene Therapy
Cell Therapy
Gene-Modified
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: EOY 2018